Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells

Leukemia Research

Volumn 22, Issue 10, 1998, Pages 939-945

  Al Alami, O ^a   Sammons, J ^a   Martin, J H ^a   Hassan, H T ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Apoptosis; CD34; Leukaemia; Nitric oxide; Taxol

Indexed keywords

CD34 ANTIGEN; NITRIC OXIDE; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ACUTE DISEASE; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; NITRIC OXIDE; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0032190755     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00092-7     Document Type: Article

References (32)

1. Leary J, Volm M, Wasserheit C, Muggia F Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology. 12(Suppl 1):1998;23-27.
2. Huizing MT, Seweberath Misser VH, Pieters RC et al. Taxanes: a new class of anti-tumour agents. Cancer Invest. 13:1995;381-404.
3. Younes A, Ayoub JP, Sarris A et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 96:1997;328-332.
4. Press OW, Le Blanc MO, Rourke TJ et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: southwest oncology group trial 9246. J Clin Oncol. 16:1998;574-578.
5. Wilson WH, Chabner BA, Bryant G et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol. 13:1995;381-386.
6. Sarris AH, Younes A, McLaughlin P et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 14:1996;233-239.
7. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-cancer Drugs. 9:1998;135-140.
8. Younes A, Rodriguez MA, McLaughlin P et al. Phase I study of fludarabine and paclitaxel for the treatment of low-grade NHL. Leuk Lymphoma. 26:1997;77-82.
9. Halicka HD, Seiter K, Feldman EJ et al. Cell cycle specificity of apoptosis during treatment of leukaemias. Apoptosis. 2:1997;25-39.
10. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M Taxol cytotoxicity on human leukaemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol. 36:1995;385-392.
11. Lieu CH, Chang YN, Lai YK Dual cytotoxic mechanisms of submicromolar taxol on human leukaemia HL-60 cells. Biochem Pharmacol. 53:1997;1587-1596.
12. Bhalla K, Huang Y, Tang C et al. Characterisation of a human myeloid leukaemia cell line highly resistant to taxol. Leukemia. 8:1994;465-475.
13. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:1997;253-257.
14. Consolini R, Pui CH, Behm FG, Raimondi SC, Campana D In vitro cytotoxicity of docetaxel in childhood acute leukaemias. J Clin Oncol. 16:1998;907-913.
15. Haase D, Feuring-Buske M, Konemann S et al. Evidence for malignant transformation in AML at the level of early haematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood. 86:1995;2906-2912.
16. Sonneveld P Multidrug resistance in acute myeloid leukaemia. Balliere's Clin Haematol. 9:1996;185-203.
17. Hassan HT, Petershofen E, Lux E, Fonatsch C, Heil G, Freund M Establishment and characterisation of a novel CD34 positive human myeloid leukaemia cell line: MHH225 growing in serum-free culture. Ann Hematol. 71:1995;111-117.
18. Pallis M, Zhu YM, Russell NH BclxL is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia. 11:1997;945-949.
19. Hassan HT, Freund M Stem cell Factor protects CD34 positive human myeloid leukaemia cells from Chemotherapy-induced Apoptosis. Pieters R Drug Resistance in Leukemia and Lymphoma. 1995;123-127 Gordon and Breach, Harwood.
20. Pae HO, Jun CD, Yoo JC et al. Enhancing and priming of macrophages for superoxide anion production by taxol. Immunopharmacol Immunotoxicol. 20:1998;27-37.
21. Hassan HT, Veit A, Maurer HR Synergistic interactions between differentiation inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J Cancer Res Clin Oncol. 117:1991;227-231.
22. Green LC, Wanger DA, Glogowski J et al. Analysis of nitrate, nitric oxide and (15 N) nitrate in biological fluids. Anal Biochem. 126:1982;131-138.
23. Al-alami O, Martin JH ZR-75-1 human breast cancer cells: expression of inducible nitric oxide synthase and effect of tamoxifen and phorbol ester on nitric oxide production. Cancer Lett. 123:1998;99-105.
24. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC Clinical toxicities encountered with paclitaxel (taxol). Sem Oncol. 20:1993;1-15.
25. Bhalla K, Ibrado AM, Bradt JE et al. PIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Leukemia. 9:1995;1851-1856.
26. Seiter K, Feldman EJ, Traganos F et al. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study with paclitaxel. Leukemia. 9:1995;1961-1966.
27. Dugas N, Mossalayi MD, Calenda A et al. Role of nitric oxide in the anti-tumoral effect of retinoic acid and 1,25-dihydroxyvitamin D3 on human promonocytic leukemic cells. Blood. 88:1996;3524-3534.
28. Kim S, Bang OS, Lee YS, Kang SS Production of inducible nitric oxide is required for monocytic differentiation of U937 cells induced by vitamin E-succinate. J Cell Sci. 111:1998;435-441.
29. Jun CD, Park SJ, Choi BM et al. Potentiation of the activity of nitric oxide by the protein kinase C activator phorbol ester in human myeloid leukemic HL-60 cells: association with enhanced fragmentation of mature genomic DNA. Cell Immunol. 176:1997;41-49.
30. Magrinat G, Mason SN, Shami PJ, Weinberg JB Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood. 80:1992;1880-1884.
31. Shami PJ, Moore JO, Gockerman JP, Hathorn JW, Misukonis MA, Weinberg JB Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk Res. 19:1995;527-533.
32. Brockhaus F, Brüne B U937 apoptotic cell death by nitric oxide: Bcl-2 down regulation and caspase activation. Exp Cell Res. 238:1998;33-41.